Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q1 2018 · 10-Q
Revenue$4.07M$4.07M+90.1% vs Q1 2017 Net Income-$13.85M-$13.85MN/M vs Q1 2017 EPS Diluted-$0.63-$0.63N/M vs Q1 2017 Operating Income-$13,501,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
Free Cash Flowderived-$17,451,000N/M Margins · derivedOperating margin-331.6%+234.7 pt vs Q1 2017
Net margin-340.3%+124.0 pt vs Q1 2017
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end